Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort

Bedaquiline is a new antibiotic that was approved for the treatment of multidrug-resistant (MDR) tuberculosis. We aimed to evaluate the short-term microbiological efficacy and the tolerability profile of bedaquiline. We performed a retrospective cohort study among patients with MDR tuberculosis rece...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical infectious diseases Vol. 60; no. 2; p. 188
Main Authors:	Guglielmetti, Lorenzo, Le Dû, Damien, Jachym, Mathilde, Henry, Benoît, Martin, Diane, Caumes, Eric, Veziris, Nicolas, Métivier, Nathalie, Robert, Jérôme
Format:	Journal Article
Language:	English
Published:	United States 15.01.2015
Subjects:	Adolescent Adult Aged Antitubercular Agents - adverse effects Antitubercular Agents - therapeutic use Cohort Studies Compassionate Use Trials Diarylquinolines - adverse effects Diarylquinolines - therapeutic use Drug-Related Side Effects and Adverse Reactions Extensively Drug-Resistant Tuberculosis - drug therapy Female France Humans Male Middle Aged Mycobacterium tuberculosis - isolation & purification Retrospective Studies Treatment Outcome Young Adult France multidrug-resistant tuberculosis TMC207 bedaquiline extensively drug-resistant tuberculosis safety
ISSN:	1537-6591, 1537-6591
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!